Artificial tears

PreclinicalSmall molecule

UUniversity Hospital of Patras

Artificial tears is one of 48 small molecule programs targeting Eye Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Diabetic RetinopathyRecruiting

AcupunctureCompleted

Eye DiseasePreclinical

Active, not recruiting

Diabetic RetinopathyPreclinical

Recruiting

AcupuncturePreclinical

Completed

Competition

Competitive Landscape

33 competitors in Diabetic Retinopathy

#DrugCompanyPhaseTrials

Precose

Bayer

Approved

1 2

Avapro

Sanofi

Approved

1 3

Farxiga

Tricor

3 5

EGRIFTA WR

TTheratechnologies

Approved

1 6

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Glucophage

Decadron

AAspen Global Incorporated

Kenalog

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2036

PreclinicalRecruiting

Diabetic Retinopathy

NCT07592273

Clinical

Trials by Indication[1]

Intravitreal Injections2 trials

Control of Pain in Intravitreal Injections Using Topical NSAIDs

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT04343222·46 enrolled

Effect of Topical and Oral Diclofenac on Pain Related to Intravitreal Injections

Completed·UUniversity Hospital of Patras·N/A·NCT02837770·76 enrolled

ART2 trials

Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT04327999·9 enrolled

Tear Osmolarity Over Time With Artificial Tears

Unknown status·HHom, Milton M., OD, FAAO·Phase 4·NCT01227226·48 enrolled

Allergic Conjunctivitis2 trials

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Completed·SSenju USA, Inc.·Phase 2·NCT00836485·122 enrolled

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

Completed·GGreiner, Jack V., OD DO PhD·Phase 4·NCT00655109·60 enrolled

ESS2 trials

Optimization of Sampling and Processing of Samples for Molecular Microbial Research on Ocular Surface Samples

Completed·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT04193774·24 enrolled

An Observational, Qualitative Study Assessing Eye Drop Administration

Unknown status·OOcular Therapeutix, Inc.··NCT05307081·300 enrolled

Ocular Hypertension1 trial

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Recruiting·EEast Coast Institute for Research·Phase 4·NCT06865144·70 enrolled

17 more indications

Open-Angle Glaucoma1 trial

Safety of Topical Insulin Drops for Open-angle Glaucoma

Active, not recruiting·—·Phase 1·NCT04118920·18 enrolled

Acupuncture1 trial

Medical vs Acupuncture for Dry Eye

Completed·NNadide Koca·N/A·NCT07185854·90 enrolled

Randomized1 trial

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Withdrawn·—·Phase 4·NCT02028312

Surgery1 trial

FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial

Completed·MMassachusetts Eye and Ear Infirmary·Phase 3·NCT04149210·2,410 enrolled

Thyroid Eye Disease1 trial

Celecoxib for Thyroid Eye Disease

Terminated·JJohns Hopkins University·Phase 2·NCT02845336·7 enrolled

Hyaluronate1 trial

Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

Completed·—·Phase 4·NCT01614847·8 enrolled

Clinical Trial1 trial

Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye

Completed·BBarbara Burgos Blasco·Phase 4·NCT05692739·116 enrolled

Glaucoma1 trial

Steroids After Laser Trabeculoplasty for Glaucoma

Completed·SStanford University·Phase 4·NCT00981435·97 enrolled

Prevention1 trial

Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

Completed·UUniversity Hospital of Patras·Phase 4·NCT03192826·79 enrolled

Viral Conjunctivitis1 trial

A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis

Completed·UUniversity of Campinas, Brazil·Phase 3·NCT01481519·100 enrolled

Treatment1 trial

Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye

Completed·—·N/A·NCT06752278·40 enrolled

Eye Disease1 trial

Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease

Completed·—·N/A·NCT06089317·200 enrolled

Anti-inflammatory Therapy1 trial

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

Completed·QQueen's University·N/A·NCT00485108·120 enrolled

Headache1 trial

Timolol Eye Drops in the Treatment of Acute Migraine Headache

Terminated·UUniversity of Missouri, Kansas City·N/A·NCT02630719·10 enrolled

TED1 trial

Reducing Adenoviral Patient Infected Days

Completed·WWashington University School of Medicine·N/A·NCT02472223·28 enrolled

Diabetic Retinopathy1 trial

An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07592273·576 enrolled

Unspecified2 trials

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Completed·AAlcon Research·Phase 3·NCT06660290·55 enrolled

Aqueous Humor Dynamics and Brimonidine

Completed·UUniversity of Nebraska·Phase 1·NCT01144494·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Artificial tears. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Artificial tears compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Artificial tears. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital of Patras company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital of Patras

Artificial tears

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2036

Trials by Indication[1]

Intravitreal Injections2 trials

ART2 trials

Allergic Conjunctivitis2 trials

ESS2 trials

Ocular Hypertension1 trial

Open-Angle Glaucoma1 trial

Acupuncture1 trial

Randomized1 trial

Surgery1 trial

Thyroid Eye Disease1 trial

Hyaluronate1 trial

Clinical Trial1 trial

Glaucoma1 trial

Prevention1 trial

Viral Conjunctivitis1 trial

Treatment1 trial

Eye Disease1 trial

Anti-inflammatory Therapy1 trial

Headache1 trial

TED1 trial

Diabetic Retinopathy1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News